

Variant: *NM_000552.5(VWF):c.2411G>T (p.Cys804Phe)*

Version: 1.0

[CA114168](#)

[313 \(ClinVar\)](#)

Gene: VWF ([HGNC:7450](#))

Condition: von Willebrand disease type 2N ([MONDO:0015631](#))

Inheritance Mode: Autosomal recessive inheritance

UID: e928df71-3a57-4f25-9303-36b69f384f15

Approved on: 2025-02-04

Published on: 2025-02-05

HGVS expressions

NM_000552.5:c.2411G>T

NM_000552.5(VWF):c.2411G>T (p.Cys804Phe)

NC_000012.12:g.6044322C>A

CM000674.2:g.6044322C>A

NC_000012.11:g.6153488C>A

CM000674.1:g.6153488C>A

NC_000012.10:g.6023749C>A

NG_009072.1:g.85349G>T

NG_009072.2:g.85349G>T

ENST00000261405.10:c.2411G>T

ENST00000261405.9:c.2411G>T

ENST00000538635.5:n.421-50388G>T

NM_000552.3:c.2411G>T

NM_000552.4:c.2411G>T

Likely Pathogenic

Met criteria codes 5

PM3_Supporting PM2_Supporting

PS3 PP4_Moderate PP3

Evidence Links 1

Expert Panel

[von Willebrand Disease VCEP](#)

Criteria Specification Information

[Criteria Specification:](#) *ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF Version 1.0.0*

[Criteria Specification Approval History](#)

[Criteria Specifications for this VCEP](#)












Evidence submitted by expert panel

von Willebrand Disease VCEP

The NM_000552.5(VWF):c.2411G>T (p.Cys804Phe) missense variant is absent from gnomAD v4.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.935, which is above the ClinGen VWD VCEP threshold of >0.644 and predicts a damaging effect on VWF function (PP3). Factor VIII binding assay performed with the C804F recombinant mutant showed severely impaired binding indicating that this variant has a damaging effect on protein function (PMID: 15461624; PS3). At least 1 patient (Patient B) with this variant displayed

excessive mucocutaneous bleeding as well as low FVIII activity (20 IU/dl) and dramatically decreased VWF:FVIII binding, which is highly specific for VWD type 2N. (PP4_moderate, PMID:15213842). Patient B (PMID: 15461624) is compound heterozygous for R854Q (classified Pathogenic by the VWD VCEP; PM3_supporting). In summary, this variant meets the criteria to be classified as Likely Pathogenic for von Willebrand disease type 2N. ACMG/AMP criteria applied as specified by the ClinGen von Willebrand disease Variant Curation Expert Panel: PM2_supporting, PP3, PM3_supporting, PP4_moderate, PS3.

Met criteria codes

- PM3_Supporting**   Patient B (PMID: 15461624) is compound heterozygous for R854Q (classified Pathogenic by the VWD VCEP) and C804F; confirmation of trans phase was not reported. 0.5pt (PM3_supporting).
- PM2_Supporting**   This variant is absent from gnomAD v4.1 (PM2_Supporting).
- PS3**   Factor VIII binding assay performed with the C804F recombinant mutant showed severely impaired binding indicating that this variant has a damaging effect on protein function (PMID: 15461624; PS3).
- Expression studies in Cos-7 cells showed C804F failed to bind FVIII. [PubMed:15461624](#) 
- PP4_Moderate**   At least 1 patient with this variant displayed excessive mucocutaneous bleeding as well as low FVIII activity (20 IU/dl) and dramatically decreased VWF:FVIII binding, which is highly specific for VWD type 2N. (PP4_moderate, PMID:15213842).
- PP3**   The computational predictor REVEL gives a score of 0.935, which is above the ClinGen VWD VCEP threshold of >0.644 and predicts a damaging effect on VWF function (PP3).

Curation History

Showing 1 to 1 of 1 rows

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.